Identification of a pyridopyrimidinone inhibitor of orthopoxviruses from a diversity-oriented synthesis library

Journal of Virology

Volumn 86, Issue 5, 2012, Pages 2632-2640

  Dower, Ken ^a   Filone, Claire Marie ^a,c   Hodges, Erin N ^a   Bjornson, Zach B ^c,d   Rubins, Kathleen H ^b   Brown, Lauren E ^a   Schaus, Scott ^a   Hensley, Lisa E ^c   Connor, John H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETYL 3 PHENYL 6 (TRIMETHYLSILYL) 2,3,7,8 TETRAHYDRO 1H PYRIDO[1,2 C]PYRIMIDIN 1 ONE; ANTIVIRUS AGENT; NEVIRAPINE; RNA POLYMERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME SUBUNIT; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; ORTHOPOXVIRUS; PREDICTION; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR STRUCTURE; ORTHOPOXVIRUS; POXVIRIDAE INFECTIONS; PYRIMIDINONES; SMALL MOLECULE LIBRARIES; VIRUS REPLICATION;

MONKEYPOX VIRUS; ORTHOPOXVIRUS; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 84857841447     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05416-11     Document Type: Article

References (33)

1. Andrei G, et al. 2006. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J. Virol. 80:9391-9401.
2. Broyles SS. 2003. Vaccinia virus transcription. J. Gen. Virol. 84:2293-2303.
3. Christen L, Seto J, Niles EG. 1990. Superinfection exclusion of vaccinia virus in virus-infected cell cultures. Virology 174:35-42.
4. Connor JH, Lyles DS. 2002. Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1. J. Virol. 76:10177-10187.
5. De Clercq E. 2001. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 14:382-397.
6. Doceul V, Hollinshead M, van der Linden L, Smith GL. Repulsion of superinfecting virions: a mechanism for rapid virus spread. Science 327:873-876.
7. Dower K, Rubins KH, Hensley LE, Connor JH. 2011. Development of vaccinia reporter viruses for rapid, high content analysis of viral function at all stages of gene expression. Antiviral Res. 91:72-80.
8. Drazen JM. 2002. Smallpox and bioterrorism. N. Engl. J. Med. 346:1262-1263.
9. Farlow J, Ichou MA, Huggins J, Ibrahim S. 2010. Comparative whole genome sequence analysis of wild-type and cidofovir-resistant monkeypoxvirus. Virol. J. 7:110.
10. Fenner F. 1982. A successful eradication campaign. Global eradication of smallpox. Rev. Infect. Dis. 4:916-930.
11. Huang CY, et al. 2008. A novel cellular protein, VPEF, facilitates vaccinia virus penetration into HeLa cells through fluid phase endocytosis. J. Virol. 82:7988-7999.
12. Huggins J, et al. 2009. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 53:2620-2625.
13. Jordan R, et al. 2009. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 53:1817-1822.
14. Kates J, Beeson J. 1970. Ribonucleic acid synthesis in vaccinia virus. I. The mechanism of synthesis and release of RNA in vaccinia cores. J. Mol. Biol. 50:1-18.
15. Katz E, Margalith E, Winer B, Goldblum N. 1973. Synthesis of vaccinia virus polypeptides in the presence of isatin-beta-thiosemicarbazone. Antimicrob. Agents Chemother. 4:44-48.
16. Keck JG, Baldick CJ, Jr, Moss B. 1990. Role of DNA replication in vaccinia virus gene expression: a naked template is required for transcription of three late trans-activator genes. Cell 61:801-809.
17. Li H, Ruan J, Durbin R. 2008. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res. 18:1851-1858.
18. McFadden, G. Killing a killer: what next for smallpox? PLoS Pathog. 6:e1000727.
19. McFadden G. 2005. Poxvirus tropism. Nat. Rev. Microbiol. 3:201-213.
20. Moss B. 2007. Poxviridae: the viruses and their replication, p 2905-2947. In Knipe DM, et al (ed), Fields virology, 5th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
21. Parker S, Nuara A, Buller RM, Schultz DA. 2007. Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2:17-34.
22. Prichard MN, Kern ER. 2005. Orthopoxvirus targets for the development of antiviral therapies. Curr. Drug Targets Infect. Disord. 5:17-28.
23. Prins C, Cresawn SG, Condit RC. 2004. An isatin-beta-thiosemicarbazoneresistant vaccinia virus containing a mutation in the second largest subunit of the viral RNA polymerase is defective in transcription elongation. J. Biol. Chem. 279:44858-44871.
24. Quenelle DC, et al. 2007. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob. Agents Chemother. 51:4118-4124.
25. Reed KD, et al. 2004. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med. 350:342-350.
26. Rietdorf J, et al. 2001. Kinesin-dependent movement on microtubules precedes actin-based motility of vaccinia virus. Nat. Cell Biol. 3:992-1000.
27. Rimoin AW, et al. 2011. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc. Natl. Acad. Sci. U. S. A. 107:16262-16267.
28. Roberts KL, Smith GL. 2008. Vaccinia virus morphogenesis and dissemination. Trends Microbiol. 16:472-479.
29. Rosemond-Hornbeak H, Moss B. 1975. Inhibition of host protein synthesis by vaccinia virus: fate of cell mRNA and synthesis of small poly(A)-rich polyribonucleotides in the presence of actinomycin D. J. Virol. 16:34-42.
30. Seet BT, et al. 2003. Poxviruses and immune evasion. Annu. Rev. Immunol. 21:377-423.
31. Taddie JA, Traktman P. 1993. Genetic characterization of the vaccinia virus DNA polymerase: cytosine arabinoside resistance requires a variable lesion conferring phosphonoacetate resistance in conjunction with an invariant mutation localized to the 3'-5' exonuclease domain. J. Virol. 67:4323-4336.
32. Vos JC, Stunnenberg HG. 1988. Derepression of a novel class of vaccinia virus genes upon DNA replication. EMBO J. 7:3487-3492.
33. Yang G, et al. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:13139-13149.